Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 674047, 13 pages
http://dx.doi.org/10.1155/2015/674047
Research Article

Diabetic Nephropathy Induced by Increased Ace Gene Dosage Is Associated with High Renal Levels of Angiotensin (1–7) and Bradykinin

1Nephrology Division, Department of Medicine, Federal University of São Paulo, Rua Botucatu 740, Vila Clementino, 04023-900 São Paulo, SP, Brazil
2Science and Technology Department, Federal University of São Paulo, São José dos Campos, SP, Brazil

Received 18 October 2014; Accepted 9 December 2014

Academic Editor: Garth Warnock

Copyright © 2015 Nádia Bertoncello et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. International Diabetes Federation, IDF Diabetes Atlas, International Diabetes Federation, Brussels, Belgium, 2013.
  2. The United States Renal Data System (USRDS), Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md, USA, 2013.
  3. E. Ritz, I. Rychlik, F. Locatelli, and S. Halimi, “End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions,” The American Journal of Kidney Diseases, vol. 34, no. 5, pp. 795–808, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Kobori, M. Kamiyama, L. M. Harrison-Bernard, and L. G. Navar, “Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy,” Journal of Investigative Medicine, vol. 61, no. 2, pp. 256–264, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. S. B. Gurley and T. M. Coffman, “The renin-angiotensin system and diabetic nephropathy,” Seminars in Nephrology, vol. 27, no. 2, pp. 144–152, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. D. J. Leehey, A. K. Singh, N. Alavi, and R. Singh, “Role of angiotensin II in diabetic nephropathy,” Kidney International Supplements, vol. 77, pp. S93–S98, 2000. View at Google Scholar
  7. S. Kagami, W. A. Border, D. E. Miller, and N. A. Noble, “Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells,” Journal of Clinical Investigation, vol. 93, no. 6, pp. 2431–2437, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. J. F. Giani, M. C. Muñoz, R. A. Pons et al., “Angiotensin-(1–7) reduces proteinuria and diminishes structural damage in renal tissue of stroke-prone spontaneously hypertensive rats,” The American Journal of Physiology—Renal Physiology, vol. 300, no. 1, pp. F272–F282, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Hayashi, K. Yamamoto, M. Ohishi et al., “The counterregulating role of ACE2 and ACE2-mediated angiotensin 1–7 signaling against angiotensin II stimulation in vascular cells,” Hypertension Research, vol. 33, no. 11, pp. 1182–1185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. Z. Su, J. Zimpelmann, and K. D. Burns, “Angiotensin-(1–7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells,” Kidney International, vol. 69, no. 12, pp. 2212–2218, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Zhang, N. A. Noble, W. A. Border, and Y. Huang, “Infusion of angiotensin-(1–7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis,” The American Journal of Physiology—Renal Physiology, vol. 298, no. 3, pp. F579–F588, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J.-Y. Moon, M. Tanimoto, T. Gohda et al., “Attenuating effect of angiotensin-(1–7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-Ay/Ta mice,” The American Journal of Physiology—Renal Physiology, vol. 300, no. 6, pp. F1271–F1282, 2011. View at Publisher · View at Google Scholar
  13. J. Zimpelmann and K. D. Burns, “Angiotensin-(1–7) activates growth-stimulatory pathways in human mesangial cells,” The American Journal of Physiology—Renal Physiology, vol. 296, no. 2, pp. F337–F346, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Esteban, S. Heringer-Walther, A. Sterner-Kock et al., “Angiotensin-(1–7) and the G protein-coupled receptor Mas are key players in renal inflammation,” PLoS ONE, vol. 4, no. 4, Article ID e5406, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. I. F. Benter, M. H. M. Yousif, C. Cojocel, M. Al-Maghrebi, and D. I. Diz, “Angiotensin-(1–7) prevents diabetes-induced cardiovascular dysfunction,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 292, no. 1, pp. H666–H672, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Shao, M. He, L. Zhou, T. Yao, Y. Huang, and L.-M. Lu, “Chronic angiotensin (1–7) injection accelerates STZ-induced diabetic renal injury,” Acta Pharmacologica Sinica, vol. 29, no. 7, pp. 829–837, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Tavares, “Polimorfismos dos genes do sistema renina-angiotensina-aldosterona e as moléculas cardiovasculares,” Revista Brasileira de Hipertensão, vol. 7, no. 3, pp. 237–242, 2000. View at Google Scholar
  18. T. S. Ahluwalia, M. Ahuja, T. S. Rai et al., “ACE variants interact with the RAS pathway to confer risk and protection against type 2 diabetic nephropathy,” DNA and Cell Biology, vol. 28, no. 3, pp. 141–150, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Rudberg, L. M. Rasmussen, H.-J. Bangstad, and R. Österby, “Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria,” Diabetes Care, vol. 23, no. 4, pp. 544–548, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. J. H. Krege, H.-S. Kim, J. S. Moyer et al., “Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis,” Hypertension, vol. 29, no. 1, part 2, pp. 150–157, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Huang, Y. Gallois, N. Bouby et al., “Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 23, pp. 13330–13334, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. J. H. Krege, S. W. M. John, L. L. Langenbach et al., “Male-female differences in fertility and blood pressure in ACE-deficient mice,” Nature, vol. 375, no. 6527, pp. 146–148, 1995. View at Publisher · View at Google Scholar · View at Scopus
  23. E. M. Oliveira, R. A. S. Santos, and J. E. Krieger, “Standardization of a fluorimetric assay for the determination of tissue angiotensin-converting enzyme activity in rats,” Brazilian Journal of Medical and Biological Research, vol. 33, no. 7, pp. 755–764, 2000. View at Google Scholar · View at Scopus
  24. M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding,” Analytical Biochemistry, vol. 72, no. 1-2, pp. 248–254, 1976. View at Publisher · View at Google Scholar · View at Scopus
  25. D. B. Vidotti, D. E. Casarini, P. C. Cristovam, C. A. Leite, N. Schor, and M. A. Boim, “High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells,” The American Journal of Physiology—Renal Physiology, vol. 286, no. 6, pp. F1039–F1045, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. F. A. Mendelsohn and C. I. Johnston, “A radiochemical renin assay,” Biochemical Journal, vol. 121, no. 2, pp. 241–244, 1971. View at Google Scholar · View at Scopus
  27. J. Friedland and E. Silverstein, “A sensitive fluorimetric assay for serum angiotensin converting enzyme,” The American Journal of Clinical Pathology, vol. 66, no. 2, pp. 416–424, 1976. View at Google Scholar · View at Scopus
  28. F. A. Ronchi, M.-C. Irigoyen, and D. E. Casarini, “Association of somatic and N-domain angiotensin-converting enzymes from Wistar rat tissue with renal dysfunction in diabetes mellitus,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 8, no. 1, pp. 34–41, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. K. B. Pedersen, S. Sriramula, K. H. Chhabra, H. Xia, and E. Lazartigues, “Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 301, no. 5, pp. R1293–R1299, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. H.-L. Tian, L.-S. Wei, Z.-X. Xu, R.-T. Zhao, D.-L. Jin, and J.-S. Gao, “Correlations between blood glucose level and diabetes signs in streptozotocin-induced diabetic mice,” Global Journal of Pharmacology, vol. 4, no. 3, pp. 111–116, 2010. View at Google Scholar · View at Scopus
  31. C. Tikellis, C. I. Johnston, J. M. Forbes et al., “Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy,” Hypertension, vol. 41, no. 3, pp. 392–397, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. R. J. Falk, J. I. Scheinman, S. M. Mauer, and A. F. Michael, “Polyantigenic expansion of basement membrane constituents in diabetic nephropathy,” Diabetes, vol. 32, supplement 2, pp. 34–39, 1983. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Zhu, Y. Kim, M. W. Steffes, T. J. Groppoli, R. J. Butkowski, and S. M. Mauer, “Glomerular distribution of type IV collagen in diabetes by high resolution quantitative immunochemistry,” Kidney International, vol. 45, no. 2, pp. 425–433, 1994. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Adler, “Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy,” Journal of the American Society of Nephrology, vol. 5, no. 5, pp. 1165–1172, 1994. View at Google Scholar · View at Scopus
  35. R. J. MacIsaac and G. Jerums, “Diabetic kidney disease with and without albuminuria,” Current Opinion in Nephrology and Hypertension, vol. 20, no. 3, pp. 246–257, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. F. S. Evangelista and J. E. Krieger, “Small gene effect and exercise training-induced cardiac hypertrophy in mice: an Ace gene dosage study,” Physiological Genomics, vol. 27, no. 3, pp. 231–236, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Wysocki, L. Garcia-Halpin, M. Ye et al., “Regulation of urinary ACE2 in diabetic mice,” The American Journal of Physiology—Renal Physiology, vol. 305, no. 4, pp. F600–F611, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Ye, J. Wysocki, J. William, M. J. Soler, I. Cokic, and D. Batlle, “Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes,” Journal of the American Society of Nephrology, vol. 17, no. 11, pp. 3067–3075, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Donoghue, F. Hsieh, E. Baronas et al., “A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9,” Circulation Research, vol. 87, no. 5, pp. E1–E9, 2000. View at Google Scholar · View at Scopus
  40. S. R. Tipnis, N. M. Hooper, R. Hyde, E. Karran, G. Christie, and A. J. Turner, “A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase,” The Journal of Biological Chemistry, vol. 275, no. 43, pp. 33238–33243, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. J. L. Zhuo, F. M. Ferrao, Y. Zheng, and X. C. Li, “New frontiers in the intrarenal renin-angiotensin system: a critical review of classical and new paradigms,” Frontiers in Endocrinology, vol. 4, article 166, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. M. J. Soler, J. Wysocki, M. Ye, J. Lloveras, Y. Kanwar, and D. Batlle, “ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice,” Kidney International, vol. 72, no. 5, pp. 614–623, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Wysocki, M. Ye, M. J. Soler et al., “ACE and ACE2 activity in diabetic mice,” Diabetes, vol. 55, no. 7, pp. 2132–2139, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Tikellis, R. Brown, G. A. Head, M. E. Cooper, and M. C. Thomas, “Angiotensin-converting enzyme 2 mediates hyperfiltration associated with diabetes,” The American Journal of Physiology—Renal Physiology, vol. 306, no. 7, pp. F773–F780, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Park, B. J. Bivona, H. Kobori et al., “Major role for ACE-independent intrarenal ANG II formation in type II diabetes,” The American Journal of Physiology—Renal Physiology, vol. 298, no. 1, pp. F37–F48, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Tikellis, K. Bialkowski, J. Pete et al., “ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes,” Diabetes, vol. 57, no. 4, pp. 1018–1025, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Ye, J. Wysocki, P. Naaz, M. R. Salabat, M. S. LaPointe, and D. Batlle, “Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination?” Hypertension, vol. 43, no. 5, pp. 1120–1125, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. J. G. Modrall, J. Sadjadi, K. B. Brosnihan et al., “Depletion of tissue angiotensin-converting enzyme differentially influences the intrarenal and urinary expression of angiotensin peptides,” Hypertension, vol. 43, no. 4, pp. 849–853, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. M. B. Monteiro, D. Senador, W. F. Zhang, M. Morris, and K. M. Elased, “Balance of ACE and ACE2 in diabetes: decreased renal ACE2 activity in hypertensive db/db diabetic mice,” Hypertension, vol. 52, article E91, 2008. View at Google Scholar
  50. M. S. Alghamri, N. M. Weir, M. P. Anstadt, K. M. Elased, S. B. Gurley, and M. Morris, “Enhanced angiotensin II-induced cardiac and aortic remodeling in ACE2 knockout mice,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 18, no. 2, pp. 138–151, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Chodavarapu, N. Grobe, H. K. Somineni, E. S. B. Salem, M. Madhu, and K. M. Elased, “Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion,” PLoS ONE, vol. 8, no. 4, Article ID e62833, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Y. Oudit, A. M. Herzenberg, Z. Kassiri et al., “Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis,” The American Journal of Pathology, vol. 168, no. 6, pp. 1808–1820, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. J. L. Guy, R. M. Jackson, K. R. Acharya, E. D. Sturrock, N. M. Hooper, and A. J. Turner, “Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence,” Biochemistry, vol. 42, no. 45, pp. 13185–13192, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. R. A. S. Santos, A. J. Ferreira, T. Verano-Braga, and M. Bader, “Angiotensin-converting enzyme 2, angiotensin-(1–7) and Mas: new players of the renin-angiotensin system,” Journal of Endocrinology, vol. 216, no. 2, pp. R1–R17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. D. W. Wong, G. Y. Oudit, H. Reich et al., “Loss of Angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury,” The American Journal of Pathology, vol. 171, no. 2, pp. 438–451, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. S. E. Park, W. J. Kim, S. W. Park et al., “High urinary ACE2 concentrations are associated with severity of glucose intolerance and microalbuminuria,” European Journal of Endocrinology, vol. 168, no. 2, pp. 203–210, 2013. View at Publisher · View at Google Scholar
  57. H. N. Reich, G. Y. Oudit, J. M. Penninger, J. W. Scholey, and A. M. Herzenberg, “Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease,” Kidney International, vol. 74, no. 12, pp. 1610–1616, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. J. A. Colucci, D. Y. Arita, T. S. Cunha et al., “Renin-angiotensin system may trigger kidney damage in NOD mice,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 12, no. 1, pp. 15–22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. C. M. Ferrario, J. Varagic, J. Habibi et al., “Differential regulation of angiotensin-(1–12) in plasma and cardiac tissue in response to bilateral nephrectomy,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 296, no. 4, pp. H1184–H1192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. B. M. Westwood and M. C. Chappell, “Divergent pathways for the angiotensin-(1–12) metabolism in the rat circulation and kidney,” Peptides, vol. 35, no. 2, pp. 190–195, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Di Salvo, A. Peterson, C. Montefusco, and M. Menta, “Intrarenal conversion of angiotensin I to angiotensin II in the dog,” Circulation Research, vol. 29, no. 4, pp. 398–406, 1971. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Rosivall, D. F. Rinder, J. Champion, M. C. Khosla, L. G. Navar, and S. Oparil, “Intrarenal angiotensin I conversion at normal and reduced renal blood flow in the dog,” The American Journal of Physiology, vol. 245, no. 3, pp. F408–F415, 1983. View at Google Scholar · View at Scopus
  63. J. Genest, M. Cantin, R. Garcia et al., “Extrarenal angiotensin-forming enzymes,” Clinical and Experimental Hypertension A, vol. 5, no. 7-8, pp. 1065–1080, 1983. View at Google Scholar · View at Scopus
  64. B. U. Wintroub, L. B. Klickstein, and K. W. K. Watt, “A human neutrophil-dependent pathway for generation of angiotensin II. Purification of the product and identification as angiotensin II,” The Journal of Clinical Investigation, vol. 68, no. 2, pp. 484–490, 1981. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Rykl, J. Thiemann, S. Kurzawski et al., “Renal cathepsin G and angiotensin II generation,” Journal of Hypertension, vol. 24, no. 9, pp. 1797–1807, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Urata, “Pathological involvement of chymase-dependent angiotensin II formation in the development of cardiovascular disease,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 1, no. 2, supplement, pp. S35–S37, 2000. View at Publisher · View at Google Scholar · View at Scopus
  67. C.-C. Wei, Q. C. Meng, R. Palmer et al., “Evidence for angiotensin-converting enzyme- and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo,” Circulation, vol. 99, no. 19, pp. 2583–2589, 1999. View at Publisher · View at Google Scholar · View at Scopus
  68. X. R. Huang, W. Y. Chen, L. D. Truong, and H. Y. Lan, “Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease,” Journal of the American Society of Nephrology, vol. 14, no. 7, pp. 1738–1747, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Sadjadi, G. L. Kramer, C.-H. Yu, M. B. Welborn III, M. C. Chappell, and J. G. Modrall, “Angiotensin converting enzyme-independent angiotensin II production by chymase is up-regulated in the ischemic kidney in renovascular hypertension,” Journal of Surgical Research, vol. 127, no. 2, pp. 65–69, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. P. C. Cristovam, C. P. Arnoni, M. C. C. De Andrade et al., “ACE-dependent and chymase-dependent angiotensin II generation in normal and glucose-stimulated human mesangial cells,” Experimental Biology and Medicine, vol. 233, no. 8, pp. 1035–1043, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. A. H. J. Danser, M. M. G. Koning, P. J. J. Admiraal, F. H. M. Derkx, P. D. Verdouw, and M. A. D. H. Schalekamp, “Metabolism of angiotensin I by different tissues in the intact animal,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 263, no. 2, part 2, pp. H418–H428, 1992. View at Google Scholar · View at Scopus
  72. Y. Uehara, S.-I. Miura, E. Yahiro, and K. Saku, “Non-ACE pathway-induced angiotensin II production,” Current Pharmaceutical Design, vol. 19, no. 17, pp. 3054–3059, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. A. R. Christlieb, A. Kaldany, and J. A. D'Elia, “Plasma renin activity and hypertension in diabetes mellitus,” Diabetes, vol. 25, no. 10, pp. 969–974, 1976. View at Publisher · View at Google Scholar · View at Scopus
  74. R. N. Re, A. A. MacPhee, and J. T. Fallon, “Specific nuclear binding of angiotensin II by rat liver and spleen nuclei,” Clinical Science, vol. 61, supplement 7, pp. 245s–247s, 1981. View at Google Scholar · View at Scopus
  75. R. Singh, A. K. Singh, N. Alavi, and D. J. Leehey, “Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose,” Journal of the American Society of Nephrology, vol. 14, no. 4, pp. 873–880, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. J. C. Q. Velez, K. J. Ryan, C. E. Harbeson et al., “Angiotensin i is largely converted to angiotensin (1–7) and angiotensin (2–10) by isolated rat glomeruli,” Hypertension, vol. 53, no. 5, pp. 790–797, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. A. C. Simões e Silva, J. S. S. Diniz, R. M. Pereira, S. V. B. Pinheiro, and R. A. S. Santos, “Circulating renin angiotensin system in childhood chronic renal failure: marked increase of angiotensin-(1–7) in end-stage renal disease,” Pediatric Research, vol. 60, no. 6, pp. 734–739, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. E. Velkoska, R. G. Dean, K. Griggs, L. Burchill, and L. M. Burrell, “Angiotensin-(1–7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy,” Clinical Science, vol. 120, no. 8, pp. 335–345, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. D. J. Campbell, D. J. Kelly, J. L. Wilkinson-Berka, M. E. Cooper, and S. L. Skinner, “Increased bradykinin and “normal” angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats,” Kidney International, vol. 56, no. 1, pp. 211–221, 1999. View at Publisher · View at Google Scholar · View at Scopus